Vis enkel innførsel

dc.contributor.authorValla, Mariten_US
dc.contributor.authorEngstrøm, Monica Jen_US
dc.contributor.authorYtterhus, Borgnyen_US
dc.contributor.authorHansen, Åse Kristin Skainen_US
dc.contributor.authorAkslen, Lars A.en_US
dc.contributor.authorVatten, Lars Johanen_US
dc.contributor.authorOpdahl, Signeen_US
dc.contributor.authorBofin, Anna M.en_US
dc.date.accessioned2018-06-13T12:05:27Z
dc.date.available2018-06-13T12:05:27Z
dc.date.issued2017-04
dc.PublishedValla M, Engstrøm MJ, Ytterhus B, Hansen ÅKS, Akslen LA, Vatten LJ, Opdahl S, Bofin A M. FGD5 amplification in breast cancer patients is associated with tumor proliferation and a poorer prognosis. Breast Cancer Research and Treatment. 2017;162(2):243-253eng
dc.identifier.issn0167-6806
dc.identifier.issn1573-7217
dc.identifier.urihttps://hdl.handle.net/1956/17793
dc.description.abstractPurpose: Proliferation is a hallmark of cancer. Using a combined genomic approach, FGD5 amplification has been identified as a driver of proliferation in Luminal breast cancer. We aimed to describe FGD5 copy number change in breast cancer, and to assess a possible association with tumour proliferation and prognosis. Methods: We used fluorescence in situ hybridization targeting FGD5 and chromosome 3 centromere (CEP3) on formalin-fixed, paraffin-embedded tissue from 430 primary breast cancers and 108 lymph node metastases, from a cohort of Norwegian breast cancer patients. We tested the association between FGD5 copy number status and proliferation (assessed by Ki67 levels and mitotic count) using Pearson’s Chi square test, and assessed the prognostic impact of FGD5 copy number change by estimating cumulative risks of death and hazard ratios. Results: We identified FGD5 amplification (defined as FGD5/CEP3 ratio ≥2 or mean FGD5/tumour cell ≥4) in 9.5% of tumours. Mitotic count and Ki67 levels were higher in tumours with FGD5 copy number increase, compared to tumours with no copy number change. After 10 years of follow-up, cumulative risk of death from breast cancer was higher among cases with FGD5 amplification [48.1% (95% CI 33.8–64.7)], compared to non-amplified cases [27.7% (95% CI 23.4–32.6)]. Conclusions: FGD5 is a new prognostic marker in breast cancer, and increased copy number is associated with higher tumour proliferation and poorer long-term prognosis.en_US
dc.language.isoengeng
dc.publisherSpringereng
dc.subjectBreast cancereng
dc.subjectFGD5eng
dc.subjectFISHeng
dc.subjectGene amplificationeng
dc.subjectProliferationeng
dc.subjectPrognosiseng
dc.titleFGD5 amplification in breast cancer patients is associated with tumor proliferation and a poorer prognosisen_US
dc.typePeer reviewed
dc.typeJournal article
dc.date.updated2018-01-18T11:20:13Z
dc.description.versionacceptedVersionen_US
dc.rights.holderCopyright 2017 Springer Science+Business Media New York
dc.identifier.doihttps://doi.org/10.1007/s10549-017-4125-8
dc.identifier.cristin1458808
dc.source.journalBreast Cancer Research and Treatment


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel